Adaptimmune is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapy products for cancer patients. With a focus on designing and delivering cell therapies, Adaptimmune aims to transform the lives of people impacted by cancer. Their main priority is to improve the outcomes of cancer patients through the use of immunotherapy.

Adaptimmune's extensive pipeline includes both clinical and preclinical products. Their clinical pipeline consists of promising therapies such as Afami-cel and ADP-A2M4CD8, targeting solid tumors. Their preclinical pipeline focuses on developing cutting-edge technology to enhance the detection and targeting of cancer cells.

By leveraging world-class expertise, Adaptimmune is advancing T-cell therapy to revolutionize cancer treatment. Their robust manufacturing process ensures the efficient supply of cell therapies to patients participating in their clinical trials. As a company committed to patients and families, Adaptimmune provides helpful resources and information to support those affected by cancer.

Stay informed about Adaptimmune's progress and breakthroughs through their news center and engage with them through their virtual events. By combining expertise, innovation, and a mission to make a difference, Adaptimmune is at the forefront of transforming the landscape of cancer treatment